Tear Replacement Therapy in Medical Support of Patients after Femto-LASIK Keratorefractive Surgery

Purpose — to analyze the effectiveness of artificial tear drops HYLOPARIN-COMOD® in the complex medical support of the FemtoLASIK operation based on monitoring of clinical, functional and morphometric indicators of the eye surface’s condition. Patients and methods. The study included 25 patients (5...

Full description

Saved in:
Bibliographic Details
Main Authors: I. E. Panova, A. V. Titov, D. R. Mirsaitova
Format: Article
Language:Russian
Published: Ophthalmology Publishing Group 2020-06-01
Series:Oftalʹmologiâ
Subjects:
Online Access:https://www.ophthalmojournal.com/opht/article/view/1207
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849399661111017472
author I. E. Panova
A. V. Titov
D. R. Mirsaitova
author_facet I. E. Panova
A. V. Titov
D. R. Mirsaitova
author_sort I. E. Panova
collection DOAJ
description Purpose — to analyze the effectiveness of artificial tear drops HYLOPARIN-COMOD® in the complex medical support of the FemtoLASIK operation based on monitoring of clinical, functional and morphometric indicators of the eye surface’s condition. Patients and methods. The study included 25 patients (50 eyes) who underwent a keratorefractive surgery (Femto-LASIK) and were prescribed instillations of artificial tear drops HILOPARIN-COMOD®. To analyze the effectiveness of artificial tear drops HYLOPARIN-COMOD® in the complex medical support of the Femto-LASIK operation based on monitoring of clinical, functional and morphometric indicators of the eye surface’s condition: UCVA, BCVA, Schirmer’s II test, tear break-up time (Norn’s test), OCT pachymetry of the cornea and corneal flap. The treatment effectiveness was evaluated at 1 day, 1 week, 1 and 3 months after the surgery. Results. As a result of the treatment, the following refractive data were obtained: UCVA increased from 0.09 ± 0.02 to 0.94 ± 0.07 on the first day after surgery and to 0.96 ± 0.04 and 0.99 ± 0.07 to 1 and 3 months of follow-up, BCVA respectively, from 0.97 ± 0.04 to 0.94 ± 0.07, 0.97 ± 0.07 and 0.99 ± 0.07 after surgery. A faster restoration of the cornea and corneal valve was revealed, as evidenced by a decrease in their thickness already in the 1st week after surgery in comparison with the control group, where were more pronounced changes occur only by the 1st and 3rd month of observation (p ≤ 0.05). There was a significant increase in the basal secretion of the lacrimal gland (Schirmer’s II test) from 10.16 ± 1.33 to 11.66 ± 1.13 and 12.88 ± 0.96 µm by 1 and 3 months after surgical treatment, respectively (p ≤ 0.05). The Norn’s test increased from 10.89 ± 1.94 to 12.78 ± 1.59 and 13.83 ± 0.5 s to 1 and 3 months of treatment, respectively (p ≤ 0.05). Conclusion. The effectiveness of the HILOPARIN-COMOD® use in the correction of the dry eye syndrome after keratorefractive operations has been proven. The obtained results clearly demonstrate that the HILOPARIN-COMOD® preparation enhances not only the stability of the tear film, but also the restoration of the OCT morphometric parameters of the thickness of the cornea and corneal flap.
format Article
id doaj-art-c1e520c61c2d4848bd3e0f8e9b019c85
institution Kabale University
issn 1816-5095
2500-0845
language Russian
publishDate 2020-06-01
publisher Ophthalmology Publishing Group
record_format Article
series Oftalʹmologiâ
spelling doaj-art-c1e520c61c2d4848bd3e0f8e9b019c852025-08-20T03:38:16ZrusOphthalmology Publishing GroupOftalʹmologiâ1816-50952500-08452020-06-0117227428010.18008/1816-5095-2020-2-274-280631Tear Replacement Therapy in Medical Support of Patients after Femto-LASIK Keratorefractive SurgeryI. E. Panova0A. V. Titov1D. R. Mirsaitova2St. Petersburg Branch of the S. Fyodorov Eye Microsurgery Federal State InstitutionSt. Petersburg Branch of the S. Fyodorov Eye Microsurgery Federal State InstitutionSt. Petersburg Branch of the S. Fyodorov Eye Microsurgery Federal State InstitutionPurpose — to analyze the effectiveness of artificial tear drops HYLOPARIN-COMOD® in the complex medical support of the FemtoLASIK operation based on monitoring of clinical, functional and morphometric indicators of the eye surface’s condition. Patients and methods. The study included 25 patients (50 eyes) who underwent a keratorefractive surgery (Femto-LASIK) and were prescribed instillations of artificial tear drops HILOPARIN-COMOD®. To analyze the effectiveness of artificial tear drops HYLOPARIN-COMOD® in the complex medical support of the Femto-LASIK operation based on monitoring of clinical, functional and morphometric indicators of the eye surface’s condition: UCVA, BCVA, Schirmer’s II test, tear break-up time (Norn’s test), OCT pachymetry of the cornea and corneal flap. The treatment effectiveness was evaluated at 1 day, 1 week, 1 and 3 months after the surgery. Results. As a result of the treatment, the following refractive data were obtained: UCVA increased from 0.09 ± 0.02 to 0.94 ± 0.07 on the first day after surgery and to 0.96 ± 0.04 and 0.99 ± 0.07 to 1 and 3 months of follow-up, BCVA respectively, from 0.97 ± 0.04 to 0.94 ± 0.07, 0.97 ± 0.07 and 0.99 ± 0.07 after surgery. A faster restoration of the cornea and corneal valve was revealed, as evidenced by a decrease in their thickness already in the 1st week after surgery in comparison with the control group, where were more pronounced changes occur only by the 1st and 3rd month of observation (p ≤ 0.05). There was a significant increase in the basal secretion of the lacrimal gland (Schirmer’s II test) from 10.16 ± 1.33 to 11.66 ± 1.13 and 12.88 ± 0.96 µm by 1 and 3 months after surgical treatment, respectively (p ≤ 0.05). The Norn’s test increased from 10.89 ± 1.94 to 12.78 ± 1.59 and 13.83 ± 0.5 s to 1 and 3 months of treatment, respectively (p ≤ 0.05). Conclusion. The effectiveness of the HILOPARIN-COMOD® use in the correction of the dry eye syndrome after keratorefractive operations has been proven. The obtained results clearly demonstrate that the HILOPARIN-COMOD® preparation enhances not only the stability of the tear film, but also the restoration of the OCT morphometric parameters of the thickness of the cornea and corneal flap.https://www.ophthalmojournal.com/opht/article/view/1207hyloparin-comod®keratorefractive surgeryfemto-lasikoct pachymetrydry eye syndrome (des)
spellingShingle I. E. Panova
A. V. Titov
D. R. Mirsaitova
Tear Replacement Therapy in Medical Support of Patients after Femto-LASIK Keratorefractive Surgery
Oftalʹmologiâ
hyloparin-comod®
keratorefractive surgery
femto-lasik
oct pachymetry
dry eye syndrome (des)
title Tear Replacement Therapy in Medical Support of Patients after Femto-LASIK Keratorefractive Surgery
title_full Tear Replacement Therapy in Medical Support of Patients after Femto-LASIK Keratorefractive Surgery
title_fullStr Tear Replacement Therapy in Medical Support of Patients after Femto-LASIK Keratorefractive Surgery
title_full_unstemmed Tear Replacement Therapy in Medical Support of Patients after Femto-LASIK Keratorefractive Surgery
title_short Tear Replacement Therapy in Medical Support of Patients after Femto-LASIK Keratorefractive Surgery
title_sort tear replacement therapy in medical support of patients after femto lasik keratorefractive surgery
topic hyloparin-comod®
keratorefractive surgery
femto-lasik
oct pachymetry
dry eye syndrome (des)
url https://www.ophthalmojournal.com/opht/article/view/1207
work_keys_str_mv AT iepanova tearreplacementtherapyinmedicalsupportofpatientsafterfemtolasikkeratorefractivesurgery
AT avtitov tearreplacementtherapyinmedicalsupportofpatientsafterfemtolasikkeratorefractivesurgery
AT drmirsaitova tearreplacementtherapyinmedicalsupportofpatientsafterfemtolasikkeratorefractivesurgery